We discuss and comment on the role agriculture will play in the containment of the CO2 problem and address protocols for terraforming the planet Earth.
A model farm template is imagined as the central methodology. A broad range of timely science news and other topics of interest are commented on.
Thursday, December 8, 2016
Magic Mushrooms lift Severe Depression
It is obvious that all natural psychoactive products need to be tested extensively against all known brain disorders. That we are only now identified magic mushrooms as proactive against the majority of severe depression cases is complete nonsense. Why did we not know this?
Science has been actively blocked from doing its job. In the meantime we test thousands of chemicals with scant indications of benefits.
The last year has seen the beginnings of a flood of medical benefits related to cannabis.
I personally no fan of recreational usage of any drug, natural or otherwise. Not even alcohol. But i also know strong indications of therapeutic value for many of the natural products. Many of those benefits are easily separated from pleasure producing aspects.
We are long overdue for a full press investigation of all such natural products in order to optimize and standardize the product..
Magic mushrooms lift severe depression in trial
Psilocybin, which is found in magic mushrooms, was administered to depression patients in a pill
A hallucinogenic chemical found in magic mushrooms has successfully lifted severe depression in previously untreatable patients.
Scientists at Imperial College London induced intense psychedelic trips in 12 people using high doses of the banned substance psilocybin.
A week after the experience all the volunteers were depression-free, and three months later five still had no symptoms of the condition.
I wouldn’t want members of the public thinking they can treat their own depressions by picking magic mushrooms
Dr Robin Carhart-Harris, Imperial College London
Published in the Lancet Psychiatry Journal, the study welcomes the results as “promising, but not completely compelling".
Its authors are now seeking further funding from the Medical Research Council and other bodies to carry out fuller trials.
They conceded, however, that the use of a placebo control, a crucial component of thorough clinical trials, would be difficult as it would be obvious who was having a hallucinogenic experience and who was not.
The psilocybin is believed to cause relief from depression by targeting receptors in the brain and disrupting the Default Mode Network, which is responsible for sense of self and is overactive in depressed people.
However, the scientists did not rule out that the psychedelic trip could have caused an “awakening”, of the kind achieved by spiritual teaching, which also helped lift the depression.
Professor David Nutt said current regulations made clinical trials extremely difficult
An estimated 350 million people worldwide are affected by the disease and the annual cost to the economy in England is thought to be around £7.5 billion, according to government figures.
About one in ten patients are resistant to treatment.
Despite the promising results, the researchers urged people not to try magic mushrooms themselves as a cure for depression.
Lead author Dr Robin Carhart-Harris, said: “Psychedelic drugs have potent psychological effects and are only given in our research when appropriate safeguards are in place, such as careful screening and professional therapeutic support.
“I wouldn’t want members of the public thinking they can treat their own depressions by picking their own magic mushrooms.
“That kind of approach could be risky.”
The volunteers in the trial had the psilocybin administered orally in capsules and were then closely monitored.
Professor David Nutt, who also took part in the research, criticised the “Kafkaesque” tangle of regulations and licencing requirements that had forced the team to wait 32 months before being allowed to conduct the trial.
“It cost £1,500 to dose each person, when in a sane world it might cost £30,” he said.
“It is important that academic research groups try to develop possible new treatments for depression as the pharmaceutical industry is pulling out of this field.
“Our study has shown psilocybin is safe and fast-acting, so may, if administered carefully, have value for these patients.”
Amanda Feiling, from the Beckley Foundation, which also took part in the research, said: “For the first time in many years, people who were at the end of the road with currently available treatments reported decreased anxiety, increased optimism and an ability to enjoy things.
“This is an unparalleled success and could revolutionise the treatment of depression.”